Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
Primary Purpose
Malignant Pleural Effusion, Exudative Pleural Effusion
Status
Terminated
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
ultrasound-guided pleural biopsy
Thoracentesis
Sponsored by
About this trial
This is an interventional diagnostic trial for Malignant Pleural Effusion
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years.
- Patients with a previous thoracentesis of a unilateral exudative pleural effusion according to Light's criteria (1) without malignant cells.
- CT thorax or PET-CT with contrast performed.
- Clinical suspicion of cancer such as (but not limited to) weight loss or PET-CT results or former cancer diagnosis.
- Patients must be able to give informed consent.
Exclusion Criteria:
- Bilateral pleural effusions.
- Known cause of pleural effusions.
- Life expectancy <3 months.
- Inability to understand written or spoken Danish.
Sites / Locations
- Næstved Sygehus, department of pulmonary medicine
- Zealand University Hospital, Roskilde, Department of Pulmonary medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Ultrasound-guided thoracentesis
Ultrasound-guided pleural biopsy and thoracentesis
Arm Description
Ultrasound guided thoracentesis
Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
Outcomes
Primary Outcome Measures
Proportion of cases with conclusive pleural workup to provide and plan treatment in patients diagnosed with malignant pleural effusion.
Our primary endpoint includes both patients who will receive palliative care and patients who will receive active treatment. For patients receiving palliative care, the presence of malignant cells is sufficient. However, for patients receiving active treatment, the primary endpoint is defined as a definite and treatment-guiding pathological result (immunohistochemistry, mutations, oncodrivers, culture and biochemistry) as decided by a multidisciplinary team conference.
Secondary Outcome Measures
Proportion of cases achieving pleural immunohistochemistry, mutations, oncodrivers and culture.
Difference in diagnostic yield between Arm A and Arm B, including subgroup analysis of MPE.
Sensitivity of ultrasound-guided closed needle biopsy of parietal pleura for diagnosing malignancy and all causes of PE.
Time from inclusion to conclusive, treatment-guiding diagnoses in patients with MPE.
The negative likelihood ratio of additional ultrasound-guided closed needle biopsy of parietal pleura in aspect of MPE.
Proportion of true non-malignant PE at end of follow-up.
Complications to pleural procedures
mortality, pneumothorax, haemoptysis, local bleeding, infections and hospital admissions
Mean volume pleural fluid drained during thoracentesis
measured in mL
Patient reported discomfort and health
measured by 5Q-5D-5L (2009 EuroQol Group EQ-5D™ Danish version).
Patient reported discomfort and health
Measured by Edmonton Symptom Assessment System (ESAS), scale 1-10, 0 being no symptoms, 10 being the worse symptoms
Patient reported cough
VAS score (visual analogue scale) for cough, 0-10, 0 being no cough, 10 being the worse cough
Pain during procedure
Measured by VAS score (visual analogue scale) for pain, 0-10, 0 being no pain, 10 being the worse pain
Willingness to repeat the procedure
Measured by 5-point Likert scale,scale 1-5, 1 being definitely willing to have the procedure again, 5 being definitely not willing to have the procedure performed again
Change in patient reported discomfort
iMeasured by Edmonton Symptom Assessment System (ESAS) and VAS score (visual analogue scale) for cough
Changes in patient reported discomfort and health
Measured by Edmonton Symptom Assessment System (ESAS) and VAS score (visual analogue scale) for cough and health measured by 5Q-5D-5L (2009 EuroQol Group EQ-5D™ Danish version).
Number of thoracenteses in these 7 days besides the study procedure.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04236037
Brief Title
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
Official Title
Ultrasound-guided Pleural Biopsy as a Supplement to Thoracentesis: A Randomised Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Terminated
Why Stopped
It is unrealistic to succeed with sufficient inclusion within the timeframe of the study, why it is terminated.
Study Start Date
November 11, 2019 (Actual)
Primary Completion Date
September 23, 2020 (Actual)
Study Completion Date
September 23, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Naestved Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The research group will investigate the diagnostic effect of early introduction of ultrasound guided pleural biopsy in the work-up of patients with one-sided pleural effusion, suspected of malignant pleural effusion.
Detailed Description
Patients with unilateral pleural effusion with high protein content (exudative pleural effusion) are likely to have malignant pleural effusion. In the Danish guidelines, patient undergo two thoracentesis before more invasive procedures, due to the relatively low incidens of pleural TB and mesothelioma. The aim of the research group is to investigate the effect of early introduction of ultrasound-guided pleural biopsy taken at the optimal sport for thoracentesis. The research group will randomise half of our patients with unilateral pleural exudate to up-front ultrasound-guided biopsy and the other half usual care eg. a second thoracentesis, to see if there is a benefit of early pleural biopsy in the work-up of patients with unilateral pleural effusion, suspected of malignant pleural effusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Pleural Effusion, Exudative Pleural Effusion
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ultrasound-guided thoracentesis
Arm Type
Active Comparator
Arm Description
Ultrasound guided thoracentesis
Arm Title
Ultrasound-guided pleural biopsy and thoracentesis
Arm Type
Experimental
Arm Description
Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
Intervention Type
Procedure
Intervention Name(s)
ultrasound-guided pleural biopsy
Intervention Description
Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
Intervention Type
Procedure
Intervention Name(s)
Thoracentesis
Intervention Description
The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
Primary Outcome Measure Information:
Title
Proportion of cases with conclusive pleural workup to provide and plan treatment in patients diagnosed with malignant pleural effusion.
Description
Our primary endpoint includes both patients who will receive palliative care and patients who will receive active treatment. For patients receiving palliative care, the presence of malignant cells is sufficient. However, for patients receiving active treatment, the primary endpoint is defined as a definite and treatment-guiding pathological result (immunohistochemistry, mutations, oncodrivers, culture and biochemistry) as decided by a multidisciplinary team conference.
Time Frame
26 weeks post randomization
Secondary Outcome Measure Information:
Title
Proportion of cases achieving pleural immunohistochemistry, mutations, oncodrivers and culture.
Time Frame
26 weeks post randomization
Title
Difference in diagnostic yield between Arm A and Arm B, including subgroup analysis of MPE.
Time Frame
26 weeks post randomization
Title
Sensitivity of ultrasound-guided closed needle biopsy of parietal pleura for diagnosing malignancy and all causes of PE.
Time Frame
26 weeks post randomization
Title
Time from inclusion to conclusive, treatment-guiding diagnoses in patients with MPE.
Time Frame
26 weeks post randomization
Title
The negative likelihood ratio of additional ultrasound-guided closed needle biopsy of parietal pleura in aspect of MPE.
Time Frame
26 weeks post randomization
Title
Proportion of true non-malignant PE at end of follow-up.
Time Frame
26 weeks post randomization
Title
Complications to pleural procedures
Description
mortality, pneumothorax, haemoptysis, local bleeding, infections and hospital admissions
Time Frame
Day 1 (1 hour after the end of procedure), 7 days and 30 days post-procedure
Title
Mean volume pleural fluid drained during thoracentesis
Description
measured in mL
Time Frame
Day 1 within 30 minutes after the end of procedure
Title
Patient reported discomfort and health
Description
measured by 5Q-5D-5L (2009 EuroQol Group EQ-5D™ Danish version).
Time Frame
Day 1within 30 minutes after the end of procedure and 7 days post-procedure
Title
Patient reported discomfort and health
Description
Measured by Edmonton Symptom Assessment System (ESAS), scale 1-10, 0 being no symptoms, 10 being the worse symptoms
Time Frame
Day 1 (immediately before procedure and within 30 minutes after the end of procedure) and 7 days post-procedure
Title
Patient reported cough
Description
VAS score (visual analogue scale) for cough, 0-10, 0 being no cough, 10 being the worse cough
Time Frame
Day 1(immediately before procedure and within 30 minutes after the end of procedure) and 7 days post-procedure
Title
Pain during procedure
Description
Measured by VAS score (visual analogue scale) for pain, 0-10, 0 being no pain, 10 being the worse pain
Time Frame
Day 1(within 30 minutes after the end of procedure)
Title
Willingness to repeat the procedure
Description
Measured by 5-point Likert scale,scale 1-5, 1 being definitely willing to have the procedure again, 5 being definitely not willing to have the procedure performed again
Time Frame
day og procedure (within 30 minutes after the end of procedure) and 1 week post-procedure
Title
Change in patient reported discomfort
Description
iMeasured by Edmonton Symptom Assessment System (ESAS) and VAS score (visual analogue scale) for cough
Time Frame
Day 1 within 30 minutes after the end of procedure
Title
Changes in patient reported discomfort and health
Description
Measured by Edmonton Symptom Assessment System (ESAS) and VAS score (visual analogue scale) for cough and health measured by 5Q-5D-5L (2009 EuroQol Group EQ-5D™ Danish version).
Time Frame
7 days post-procedure
Title
Number of thoracenteses in these 7 days besides the study procedure.
Time Frame
7 days post-procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years.
Patients with a previous thoracentesis of a unilateral exudative pleural effusion according to Light's criteria (1) without malignant cells.
CT thorax or PET-CT with contrast performed.
Clinical suspicion of cancer such as (but not limited to) weight loss or PET-CT results or former cancer diagnosis.
Patients must be able to give informed consent.
Exclusion Criteria:
Bilateral pleural effusions.
Known cause of pleural effusions.
Life expectancy <3 months.
Inability to understand written or spoken Danish.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Uffe Bødtger, MD, PhD,
Organizational Affiliation
Department of Respiratory Medicine; Naestved Hospital, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Næstved Sygehus, department of pulmonary medicine
City
Næstved
State/Province
Region Sjælland
ZIP/Postal Code
4700
Country
Denmark
Facility Name
Zealand University Hospital, Roskilde, Department of Pulmonary medicine
City
Roskilde
State/Province
Zealand
ZIP/Postal Code
4000
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
4642731
Citation
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972 Oct;77(4):507-13. doi: 10.7326/0003-4819-77-4-507. No abstract available.
Results Reference
background
Learn more about this trial
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
We'll reach out to this number within 24 hrs